Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — IPO Roadshow (December 2024)
11 slides from Cytosorbents's IPO roadshow presentation, Dec 9, 2024
Slide 1: Rights Offering Overview December 5, 2024
NASDAQ: CTSO Rights Offering Overview December 5, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc . and CytoSorbents Europe GmbH that are not historical facts are forward - looking statements and are subject to risks and uncertainties that could cause
Slide 3: CytoSorbents at a Glance
3 Cyto Sorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology o Cyto Sorb • Treatmen
Slide 4: About CytoSorbents Rights Offering
About Cyto Sorbents Rights Offering
Slide 5: What is a Rights Offering?
5 What is a Rights Offering? CytoSorbents issues a dividend in the form of a “right” to every stockholder and certain warrant holders (together “Sharehold ers ”) of record. Each right gives the Shareholder an opportunity, but not the obligation, to purchase securities of CytoSorbents in proportion t
Slide 6: This offering is intended to strengthen CytoSorbents' balance sheet
6 This offering is intended to strengthen CytoSorbents’ balance sheet Net proceeds will be used to satisfy a debt covenant where proceeds of $3.0 million to $5.0 million will unlock $3.0 to $5.0 million in restricted cash currently on our balance sheet on a dollar - for - dollar basis. For example,
Slide 7: Structure of CytoSorbents' Transaction Overview
7 Structure of Cyto Sorbents ’ Transaction Overview Subscription Right Choices Unit Definition Unit Pricing Each unit will consist of: • One share of common stock • A non - transferrable Series A Right Warrant to purchase one share of common stock • A non - transferrable Series B Right Warrant to pu
Slide 8: Series A and B Right Warrant Pricing
8 Series A and B Right Warrant Pricing Exercise Price Transaction Expiration Right Warrants 90% of the 5 - day volume weighted average price of the Company’s common stock over the 5 - trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but
Slide 9: Maximum issuance of 6.25 million Units and 12.5 million shares
9 We will issue a maximum of 6.25 million Units and a maximum of 12.5 million shares of Common Stock in this offering, includin g t he shares of Common Stock comprising the Units as well as the shares of Common Stock issuable upon exercise of the Right Warrants. If the Units are fully subscribed the
Slide 10: Key Dates
10 Key Dates Ownership Date (must hold or buy CTSO by stock market close to participate): December 13, 2024 Shareholder Record Date/Settlement Date (must own by the 13 th ): December 16, 2024 Subscription Period Begins: December 16, 2024 Unit Subscription Right Warrant Offering Expiration Date* Janu
Slide 11: For More Information
For More Information 11 Aman Patel – ICR HealthCare ir@cytosorbents.com Information Agent Deal Manager for the Rights Offering Cyto Sorbents Investor Relations Moody Capital Solutions, Inc. info@moodycapital.com D.F. King & Co., Inc. (800) 549 - 6864 (toll - free) or (212) 269 - 5550 (broker - deale